Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844983 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
A Phase 2 study, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT04844983 is a Phase 2 study that has completed, run by Sirnaomics. The registered enrollment target is 44 participants.
The verdict
NCT04844983, a Phase 2 study, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).
Interventions
- DRUG STP705
- OTHER Placebo Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04844983
The ClinicalTrials.gov registry entry for NCT04844983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which STP705 is the first listed.
NCT04844983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04844983 about?
NCT04844983 is a clinical study titled "A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC". The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).
What is the current status of trial NCT04844983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2021-05-18. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT04844983?
The interventions under investigation include: STP705 (DRUG), Placebo Saline (OTHER).
Who is sponsoring clinical trial NCT04844983?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.